Becton, Dickinson and Co. | BDX - Sales Revenues


Becton, Dickinson and Co. reported $4.7B in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
Abbott USD 11.16B 300M Mar/2026
Agilent USD 1.84B 37M Mar/2026
Align Technology USD 1.04B 10M Mar/2026
AngioDynamics USD 79.43M 3.72M Sep/2025
Avanos Medical USD 182.2M 1.3M Mar/2026
Baxter International USD 2.7B 270M Mar/2026
Becton, Dickinson and Co. USD 4.7B 600M Mar/2026
Bio-Rad Laboratories USD 592.1M 101.1M Mar/2026
Boston Scientific USD 5.2B 90M Mar/2026
Cooper Companies USD 1.08B 57.4M Mar/2026
Danaher USD 5.95B 890M Mar/2026
Dentsply International USD 880M 81M Mar/2026
Dexcom USD 1.19B 70M Mar/2026
Edwards Lifesciences USD 1.65B 80M Mar/2026
Globus Medical USD 759.85M 66.55M Mar/2026
Insulet USD 761.7M 22.1M Mar/2026
Integra LifeSciences USD 391.9M 43M Mar/2026
Intuitive Surgical USD 2.77B 100M Mar/2026
J&J USD 24.1B 500M Mar/2026
Medtronic USD 9.8B 800M Mar/2026
Solventum Corp USD 2.01B 20M Mar/2026
Stryker USD 6B 1.2B Mar/2026
Tandem Diabetes Care USD 247.22M 43.18M Mar/2026
Teleflex USD 548.3M 20.68M Mar/2026
Terumo JPY 300.32B 3.69B Mar/2026
Thermo Fisher Scientific USD 11.01B 1.2B Mar/2026
Zimmer Biomet Holdings USD 2.09B 150M Mar/2026